InMed Pharmaceuticals Inc. news
VANCOUVER, British Columbia, Nov. 21, 2022 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a leader in the pharmaceutical research, development and manufacturing of rare cannabinoids and cannabinoid analogs, today announced the closing of its previously announced private placement with two healthcare-focused institutional investors for the issuance and sale of 1,818,185 of its c
VANCOUVER, British Columbia, Nov. 18, 2022 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a leader in the pharmaceutical research, development and manufacturing of rare cannabinoids and cannabinoid analogs, today announced that it has entered into a securities purchase agreement with two healthcare-focused institutional investors for the issuance and sale of 1,818,185 of i
- Targeting neurodegenerative diseases such as Alzheimer’s, Huntington’s and Parkinson’s
- Identified two lead cannabinoid analog compounds for in vivo studies
- NSERC grant funding supports InMed’s collaborative research projects with Dr. Kumar from University of British Columbia (UBC)
VANCOUVER, British Columbia, Nov. 16, 2022 (GLOBE NEWS
- Phase 2 clinical trial recently expanded to include adolescents following independent review of early safety data
- First adolescent patient with EB enrolled into clinical trial and completed treatment
- International patent granted for the use of cannabinol for the treatment of epidermolysis bullosa
VANCOUVER, British Columbia, July 25, 2022 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc.
- Produces highly pure d9-dominant THCV, a non-intoxicating cannabinoid
- Bolsters Company’s commercial portfolio, which also includes CBDV, CBC and CBT
- THCV has been researched for a variety of potential benefits
VANCOUVER, British Columbia, June 09, 2022 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (N